

Ribavirin treatment for chronic hepatitis C

Lancet, The

337, 1058-1061

DOI: [10.1016/0140-6736\(91\)91707-2](https://doi.org/10.1016/0140-6736(91)91707-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Antiviral Therapy and Prophylaxis. <i>Pediatric and Adolescent Medicine</i> , 1993, 4, 37-48.	0.4	0
2	Hepatitis C and its Causative Agent. <i>Acta Clinica Belgica</i> , 1991, 46, 203-208.	0.5	4
3	The Activity of Ribavirin against the Human Immunodeficiency Virus: A Review of Laboratory and Clinical Experience. <i>Antiviral Chemistry and Chemotherapy</i> , 1991, 2, 257-263.	0.3	4
4	Clinical pharmacology and therapeutics. <i>Postgraduate Medical Journal</i> , 1991, 67, 1042-1054.	0.9	6
5	Chronic Hepatitis and Cirrhosis. , 1992, , 281-415.		0
6	Chronic hepatitis B and C. <i>Postgraduate Medicine</i> , 1992, 92, 75-82.	0.9	9
7	Hepatitis C: Virology, Epidemiology, Clinical Course, and Treatment. <i>Scandinavian Journal of Gastroenterology</i> , 1992, 27, 337-342.	0.6	21
8	If You Cannot Grow it, Clone it! Hepatitis C Update. <i>Baylor University Medical Center Proceedings</i> , 1992, 5, 3-12.	0.2	1
10	A pilot study of ribavirin therapy for chronic hepatitis C. <i>Hepatology</i> , 1992, 16, 649-654.	3.6	284
11	Hepatitis C viraemia rebound after "successful" interferon therapy in patients with chronic non-A, non-B hepatitis. <i>Journal of Medical Virology</i> , 1992, 37, 210-214.	2.5	53
12	Pilot study of ribavirin and interferon- β for chronic hepatitis B. <i>Hepatology</i> , 1993, 18, 258-263.	3.6	32
13	Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. <i>Journal of Medical Virology</i> , 1993, 41, 99-102.	2.5	87
14	Chronic hepatitis in haemophilia. <i>Blood Reviews</i> , 1993, 7, 243-250.	2.8	25
15	Chronic hepatitis. <i>Disease-a-Month</i> , 1993, 39, 59-125.	0.4	1
16	Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. <i>Journal of Hepatology</i> , 1993, 19, 408-412.	1.8	64
17	Antiviral therapy of hepatitis C " present and future. <i>Journal of Hepatology</i> , 1993, 17, S130-S136.	1.8	47
18	Recurrent HCV hepatitis after liver transplantation. <i>Lancet, The</i> , 1993, 341, 378-379.	6.3	11
19	Ribavirin for syncytial giant cell hepatitis. <i>Lancet, The</i> , 1993, 341, 640-641.	6.3	15

#	ARTICLE	IF	CITATIONS
20	Treatment of chronic viral hepatitis. <i>Journal of Antimicrobial Chemotherapy</i> , 1993, 32, 107-120.	1.3	6
21	Serum HCV RNA Levels in Patients with Chronic Hepatitis C Given a Second Course of Interferon alpha-2b Treatment after Relapse following Initial Treatment. <i>Scandinavian Journal of Infectious Diseases</i> , 1993, 25, 25-30.	1.5	37
22	Viral markers in the treatment of hepatitis B and C.. <i>Gut</i> , 1993, 34, S26-S35.	6.1	20
23	Historical treatment of chronic hepatitis B and chronic hepatitis C.. <i>Gut</i> , 1993, 34, S69-S73.	6.1	7
24	Diagnosis and Treatment of the Major Hepatotropic Viruses. <i>American Journal of the Medical Sciences</i> , 1993, 306, 248-261.	0.4	6
25	A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. <i>Gastroenterology</i> , 1993, 105, 507-512.	0.6	136
26	Managing chronic hepatitis C virus infection.. <i>BMJ: British Medical Journal</i> , 1993, 306, 469-470.	2.4	11
27	Hepatitis C: Recent Advances. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1993, 4, 195-197.	0.3	1
28	Hepatitis C Treatment. <i>Current Studies in Hematology and Blood Transfusion</i> , 1994, 61, 121-136.	0.2	1
29	Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. <i>Journal of Medical Virology</i> , 1994, 42, 299-305.	2.5	240
30	Hepatitis C virus genotypes: An investigation of type-specific differences in geographic origin and disease. <i>Hepatology</i> , 1994, 19, 13-18.	3.6	481
31	Viral hepatitis. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1994, 78, 682-695.	0.6	24
32	Treatment of chronic viral hepatitis. <i>Bailliere's Clinical Gastroenterology</i> , 1994, 8, 233-253.	0.9	9
33	Interferon therapy in chronic hepatitis C virus infection. <i>FEMS Microbiology Reviews</i> , 1994, 14, 279-288.	3.9	27
34	A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. <i>Kidney International</i> , 1994, 46, 504-511.	2.6	116
35	Chronic hepatitis C. <i>Disease-a-Month</i> , 1994, 40, 122-196.	0.4	5
36	Nucleoside analogs in the treatment of chronic viral hepatitis efficiency and complications. <i>Journal of Hepatology</i> , 1994, 21, 142-144.	1.8	21
37	Therapy of chronic hepatitis B with a 6-month course of ribavirin. <i>Journal of Hepatology</i> , 1994, 21, 145-150.	1.8	38

#	ARTICLE	IF	CITATIONS
38	Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 1994, 21, 1109-1112.	1.8	65
40	Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1994, 9, 587-591.	1.4	47
41	Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents. <i>Antiviral Research</i> , 1994, 24, 245-257.	1.9	25
42	New approaches to the treatment of chronic viral hepatitis B and C. <i>American Journal of Medicine</i> , 1994, 96, S47-S51.	0.6	21
43	The Potential Role of Cytokines in the Treatment of Viral Infections. <i>BioDrugs</i> , 1994, 1, 15-30.	0.7	6
45	Ribavirin as Therapy for Chronic Hepatitis C. <i>Annals of Internal Medicine</i> , 1995, 123, 897.	2.0	310
46	Hepatitis C Virus Infection and Disease in Renal Transplantation. <i>Nephron</i> , 1995, 71, 386-394.	0.9	31
47	Efficacy of an analysis of lymphocyte subsets in predicting the clinical response to ð±interferon therapy in thalassaemia patients with chronic infection by hepatitis C virus: a pilot study. <i>British Journal of Haematology</i> , 1995, 89, 291-298.	1.2	6
48	Ribavirin therapy for hepatitis C infection following liver transplantation. <i>Transplant International</i> , 1995, 8, 61-64.	0.8	67
49	Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. <i>Journal of Medical Virology</i> , 1995, 46, 43-47.	2.5	98
50	Management of patients with HIV and/or hepatitis. <i>Haemophilia</i> , 1995, 1, 26-34.	1.0	4
51	Management of chronic hepatitis C. <i>Haemophilia</i> , 1995, 1, 30-35.	1.0	3
52	Efficacy and tolerance of ð±-2b interferon therapy on HCV infection of hemodialyzed patients. <i>Kidney International</i> , 1995, 47, 1412-1418.	2.6	102
53	Hepatitis C: Clinical aspects. <i>Journal of Infection</i> , 1995, 30, 103-106.	1.7	2
54	Treatment and prevention of chronic viral hepatitis. , 1995, 65, 47-73.		23
55	Rebound of hepatitis C virus RNA in serum after withdrawal of interferon in patients with advanced liver disease. <i>International Hepatology Communications</i> , 1995, 3, 26-34.	0.7	0
56	Hepatitis C. <i>Postgraduate Medicine</i> , 1995, 98, 79-94.	0.9	6
57	The management of chronic hepatitis C virus infection.. <i>Gut</i> , 1995, 37, 449-454.	6.1	35

#	ARTICLE	IF	CITATIONS
58	HEPATITIS C: An Overview. Annual Review of Medicine, 1995, 46, 309-317.	5.0	23
59	Hepatitis C: Natural History of a Unique Infection. Clinical Infectious Diseases, 1995, 20, 1361-1370.	2.9	47
60	Orthotopic liver transplantation for chronic hepatitis in two patients with common variable immunodeficiency. Gastroenterology, 1995, 108, 879-884.	0.6	41
61	Combined Alpha-interferon and Ribavirin Treatment in Chronic Hepatitis C: A Pilot Study. Scandinavian Journal of Infectious Diseases, 1995, 27, 325-329.	1.5	35
62	Genetic diversity of hepatitis C virus: implications for pathogenesis, treatment, and prevention. Lancet, The, 1995, 345, 562-566.	6.3	21
64	Fixed versus titrated interferon- α 2B in chronic hepatitis C. A randomized controlled multicenter trial. Journal of Hepatology, 1996, 25, 275-282.	1.8	15
65	Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. Journal of Hepatology, 1996, 25, 591-598.	1.8	319
66	New approaches to the use of ribavirin. Seminars in Pediatric Infectious Diseases, 1996, 7, 114-120.	1.7	6
67	Pathophysiology and Treatment of Hepatitis C. Drugs, 1996, 52, 1-8.	4.9	8
68	Interferon and Other Therapies for Hepatitis B and Hepatitis C Infections. Clinics in Laboratory Medicine, 1996, 16, 465-491.	0.7	5
69	Incidence and Treatment of Recurrent Hepatitis C after Liver Transplantation. Journal of Transplant Coordination, 1996, 6, 24-27.	0.2	0
70	Trends in Infectious Disease and Cancer in HIV Infection. Annals of Internal Medicine, 1996, 125, 777.	2.0	0
71	Acyclovir Suppresses Subclinical Shedding of Herpes Simplex Virus. Annals of Internal Medicine, 1996, 125, 776.	2.0	2
72	Exacerbation of Pseudogout by Granulocyte Colony-Stimulating Factor. Annals of Internal Medicine, 1996, 125, 781.	2.0	20
73	Section Review Anti-infectives: Developments in viral hepatitis during 1995. Expert Opinion on Therapeutic Patents, 1996, 6, 739-746.	2.4	5
74	Acyclovir Suppresses Subclinical Shedding of Herpes Simplex Virus. Annals of Internal Medicine, 1996, 125, 776.	2.0	10
75	Allogeneic Bone Marrow Transplantation in Chronic Lymphocytic Leukemia. Annals of Internal Medicine, 1996, 125, 780.	2.0	1
76	Trends in Infectious Disease and Cancer in HIV Infection. Annals of Internal Medicine, 1996, 125, 777.	2.0	1

#	ARTICLE	IF	CITATIONS
77	Shark Cartilage-Induced Hepatitis. <i>Annals of Internal Medicine</i> , 1996, 125, 780.	2.0	28
78	Hyperkalemia and Trimethoprim-Sulfamethoxazole. <i>Annals of Internal Medicine</i> , 1996, 125, 778.	2.0	0
79	Mixed Cryoglobulinemia and Membranoproliferative Glomerulonephritis Associated with Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 1996, 125, 781.	2.0	17
80	Treatment of chronic hepatitis C: another therapeutic option. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 62-64.	0.4	4
81	Consensus symposium on combined antiviral therapy. <i>Antiviral Research</i> , 1996, 29, 5-29.	1.9	20
82	Summary: antiviral treatment of hepatitis C virus. <i>Antiviral Research</i> , 1996, 29, 77-82.	1.9	5
83	Interferon-ribavirin combination therapy for chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , 1996, 41, 131S-134S.	1.1	25
84	Prolonged therapy of chronic hepatitis C with ribavirin. <i>Journal of Viral Hepatitis</i> , 1996, 3, 247-252.	1.0	63
85	Interferon therapy for chronic hepatitis C. <i>Bailliere's Clinical Gastroenterology</i> , 1996, 10, 289-298.	0.9	0
86	New treatments for chronic viral hepatitis B and C. <i>Bailliere's Clinical Gastroenterology</i> , 1996, 10, 299-333.	0.9	3
87	11 Transfusion-transmitted disease. <i>Best Practice and Research: Clinical Haematology</i> , 1996, 9, 369-394.	1.1	15
88	Beneficial effect of ribavirin on hepatitis C-associated cryoglobulinemia after liver transplantation. <i>Liver Transplantation</i> , 1996, 2, 263-268.	1.9	11
89	Adding interventions to interferon in chronic HCV infections.. <i>Gut</i> , 1996, 39, 769-769.	6.1	0
90	Oral Ribavirin for Prevention of Severe Liver Disease Caused by Hepatitis C Virus During Allogeneic Bone Marrow Transplantation. <i>Clinical Infectious Diseases</i> , 1996, 23, 167-169.	2.9	29
92	Interferon Treatment of Viral Hepatitis. <i>BioDrugs</i> , 1997, 8, 16-23.	2.2	1
93	TREATMENT OF ACUTE AND CHRONIC HEPATITIS C. <i>Clinics in Liver Disease</i> , 1997, 1, 615-630.	1.0	17
94	Limited benefits of INF- β therapy in renal graft candidates with chronic viral hepatitis B or C. <i>Transplantation Proceedings</i> , 1997, 29, 777-780.	0.3	20
95	Hepatitis-C-associated cryoglobulinemia after liver transplantation. <i>Transplantation Proceedings</i> , 1997, 29, 2684-2686.	0.3	4

#	ARTICLE	IF	CITATIONS
96	Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. <i>Journal of Hepatology</i> , 1997, 26, 961-966.	1.8	219
97	Chronic hepatitis C virus disease: An evaluation of procedures for diagnosis and treatment. <i>Netherlands Journal of Medicine</i> , 1997, 51, 213-224.	0.6	5
99	Inhibition of coxsackievirus B3 carrier state infection of cultured human myocardial fibroblasts by ribavirin and human natural interferon- β . <i>Antiviral Research</i> , 1997, 34, 101-111.	1.9	29
100	Retreatment of chronic hepatitis C with ribavirin followed by interferon. <i>Hepatology Research</i> , 1997, 7, 130-135.	1.8	3
101	Ribavirin plus human leucocyte interferon alpha for the treatment of interferon resistant chronic hepatitis C: a controlled trial. <i>Hepatology Research</i> , 1997, 8, 106-112.	1.8	10
102	Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin. <i>Journal of Viral Hepatitis</i> , 1997, 4, 243-253.	1.0	14
103	Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. <i>Hepatology</i> , 1997, 26, 473-477.	3.6	360
104	Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. <i>Hepatology</i> , 1997, 26, 500-504.	3.6	261
105	Therapy of hepatitis C: Alpha interferon and ribavirin. <i>Hepatology</i> , 1997, 26, 1085-1115.	3.6	89
106	Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized, controlled trial. <i>Hepatology</i> , 1998, 28, 341-346.	3.6	57
107	Management of hepatitis C. <i>Journal of Viral Hepatitis</i> , 1998, 5, 73-82.	1.0	23
108	Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. <i>Journal of Viral Hepatitis</i> , 1998, 5, 193-198.	1.0	59
109	HEPATITIS IN HAEMOPHILIA. <i>British Journal of Haematology</i> , 1998, 103, 1-9.	1.2	16
110	Association between oral poliovaccine and Guillain-Barré syndrome?. <i>Lancet, The</i> , 1998, 351, 79-80.	6.3	23
111	Efficacy of combined interferon and ribavirin for treatment of hepatitis C. <i>Lancet, The</i> , 1998, 351, 78-79.	6.3	26
112	Randomised, double-blind, placebo-controlled trial of interferon β 2b with and without ribavirin for chronic hepatitis C. <i>Lancet, The</i> , 1998, 351, 83-87.	6.3	623
113	Combination therapy of chronic hepatitis C: an important step but not the final goal!. <i>Journal of Hepatology</i> , 1998, 29, 1010-1014.	1.8	25
114	Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. <i>Journal of Hepatology</i> , 1998, 29, 29-35.	1.8	67

#	ARTICLE	IF	CITATIONS
115	Interferon- $\hat{\pm}$ -2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon- $\hat{\pm}$ alone: an italian multicenter, randomized, controlled, clinical study. American Journal of Gastroenterology, 1998, 93, 2445-2451.	0.2	49
116	Interferon- $\hat{\pm}$ -2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon- $\hat{\pm}$ alone: an italian multicenter, randomized, controlled, clinical study. American Journal of Gastroenterology, 1998, 93, 2445-2451.	0.2	48
117	Treatment of Chronic Viral Hepatitis. Antiviral Chemistry and Chemotherapy, 1998, 9, 449-460.	0.3	24
118	Therapy of Viral Hepatitis. Digestion, 1998, 59, 563-578.	1.2	117
119	Combination therapy for chronic hepatitis C: interferon and ribavirin. British Journal of Hospital Medicine, 1999, 60, 357-361.	0.3	19
120	Future Directions in the Treatment of Patients with Chronic Hepatitis C Virus Infection. Canadian Journal of Gastroenterology & Hepatology, 1999, 13, 57-62.	1.8	8
121	Hepatitis Viruses. , 0, , 187-233.		0
122	Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial. Liver International, 1999, 19, 275-280.	1.9	29
124	Treatment of chronic hepatitis C: Impact of combination therapy. Current Gastroenterology Reports, 1999, 1, 9-14.	1.1	2
125	Correlation of Interferon-Induced Expression of MxA mRNA in Peripheral Blood Mononuclear Cells with the Response of Patients with Chronic Active Hepatitis C to IFN-alpha Therapy. Journal of Interferon and Cytokine Research, 1999, 19, 243-251.	0.5	66
126	Long-term Re-treatment with Interferon and Ribavirin Combination Therapy in Patients with Chronic Hepatitis C who are Non-responders to Interferon Alone: a Preliminary Study. Scandinavian Journal of Infectious Diseases, 1999, 31, 359-361.	1.5	11
127	Intravenous Recombinant Interferon-Beta versus Interferon-Alpha-2b and Ribavirin in Combination for Short-Term Treatment of Chronic Hepatitis C Patients Not Responding to Interferon-Alpha. Scandinavian Journal of Gastroenterology, 1999, 34, 928-933.	0.6	29
128	Treatment with Interferon-Alpha2a Alone or Interferon-Alpha2a plus Ribavirin in Patients with Chronic Hepatitis C Previously Treated with Interferon-Alpha2a. Scandinavian Journal of Gastroenterology, 1999, 34, 194-198.	0.6	37
130	Interferon- $\hat{\pm}$ plus ribavirin in chronic hepatitis C resistant to previous interferon- $\hat{\pm}$ course: results of a randomized multicenter trial. Journal of Hepatology, 1999, 30, 788-793.	1.8	45
131	A randomized trial of ribavirin and interferon- $\hat{\pm}$ vs. interferon- $\hat{\pm}$ alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Journal of Hepatology, 1999, 31, 1-7.	1.8	70
132	COMBINATION TREATMENT WITH INTERFERON AND RIBAVIRIN FOR CHRONIC HEPATITIS C. Clinics in Liver Disease, 1999, 3, 811-826.	1.0	23
133	Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. American Journal of Medicine, 1999, 107, 112-118.	0.6	74
134	Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Journal of Viral Hepatitis, 2000, 7, 167-174.	1.0	68

#	ARTICLE	IF	CITATIONS
135	Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. <i>Liver</i> , 2000, 20, 427-436.	0.1	20
136	Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C. <i>Hepatology</i> , 2000, 31, 1338-1344.	3.6	55
137	Is ribavirin treatment really effective for chronic hepatitis B?. <i>Journal of Gastroenterology</i> , 2000, 35, 404-406.	2.3	1
138	Increased Hepatic Iron Deposition Resulting From Treatment of Chronic Hepatitis C With Ribavirin. <i>American Journal of Clinical Pathology</i> , 2000, 113, 35-39.	0.4	49
139	Treatment of Chronic Hepatitis C Virus Infection. <i>Annals of Pharmacotherapy</i> , 2000, 34, 1156-1164.	0.9	8
140	Additive Effect of Neutralizing Antibody and Antiviral Drug Treatment in Preventing Virus Escape and Persistence. <i>Journal of Virology</i> , 2000, 74, 5896-5901.	1.5	28
141	Retreatment with Interferon-Alpha and Ribavirin in Primary Interferon-Alpha Non-Responders with Chronic Hepatitis C. <i>Digestion</i> , 2000, 61, 90-97.	1.2	25
142	Biochemical and virological changes in serum of nonresponder or relapser chronic hepatitis C patients retreated with interferon and ribavirin followed by interferon alone. <i>American Journal of Gastroenterology</i> , 2000, 95, 2399-2400.	0.2	3
143	Current therapy for chronic hepatitis C. <i>Gastroenterology</i> , 2000, 118, S104-S114.	0.6	52
144	Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. <i>Journal of Hepatology</i> , 2000, 33, 448-455.	1.8	31
145	Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. <i>Journal of Hepatology</i> , 2000, 33, 791-798.	1.8	87
146	Pathogenesis, diagnosis and management of hepatitis C. <i>Journal of Hepatology</i> , 2000, 32, 98-112.	1.8	148
147	Amantadine for chronic hepatitis C: a magic bullet or yet another dead duck?. <i>Journal of Hepatology</i> , 2001, 35, 527-530.	1.8	22
148	Efficacy of High-Dose Interferon in Combination With Ribavirin in Patients With Chronic Hepatitis C Resistant To Interferon Alone. <i>American Journal of Gastroenterology</i> , 2001, 96, 1143-1149.	0.2	19
149	Ribavirin - current status of a broad spectrum antiviral agent. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 1317-1324.	0.9	169
150	Combination of interferon alfa-2b and ribavirin in relapsed or nonresponding chronic hepatitis C patients following interferon therapy. <i>Medical Journal of Indonesia</i> , 0, 10, 214.	0.2	0
151	Ribavirin enhances interferon- β levels in patients with chronic hepatitis C treated with interferon- α . <i>Journal of Biomedical Science</i> , 2001, 8, 484-491.	2.6	7
152	Management Strategies for Ribavirin-Induced Hemolytic Anemia in the Treatment of Hepatitis C: Clinical and Economic Implications. <i>Value in Health</i> , 2001, 4, 376-384.	0.1	19

#	ARTICLE	IF	CITATIONS
153	Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy. <i>Journal of Viral Hepatitis</i> , 2001, 8, 120-131.	1.0	40
154	Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study. <i>Journal of Viral Hepatitis</i> , 2001, 8, 284-286.	1.0	16
155	A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. <i>Hepatology</i> , 2001, 34, 377-384.	3.6	58
156	Chronic hepatitis C: current status and rationale for antiviral therapy. <i>The European Journal of Surgery</i> , 2001, 167, 49-55.	1.0	0
157	Long-term Combination of Interferon Alfa-2b and Ribavirin for Hepatitis C Recurrence in Liver Transplant Patients. <i>American Journal of Transplantation</i> , 2001, 1, 350-355.	2.6	31
158	Ribavirin Enhances Interferon- γ Levels in Patients with Chronic Hepatitis C Treated with Interferon- α . <i>Journal of Biomedical Science</i> , 2001, 8, 484-491.	2.6	14
159	Clinical guidelines on the management of hepatitis C. <i>Gut</i> , 2001, 49, 1i-21.	6.1	121
160	Treatment of Chronic Viral Hepatitis. <i>Antiviral Chemistry and Chemotherapy</i> , 2001, 12, 201-212.	0.3	16
161	Ribavirin in Cancer Immunotherapies Controlling Nitric Oxide Helps Generate Cytotoxic Lymphocyte. <i>Cancer Biology and Therapy</i> , 2002, 1, 626-630.	1.5	5
162	Treatment of Hepatitis C Virus Genotype 4-Related Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, 82-85.	1.1	41
163	Ribavirin with or without alpha interferon for chronic hepatitis C. <i>The Cochrane Library</i> , 2002, , CD002234.	1.5	14
164	Interferon- α 2b Plus Ribavirin. <i>Drugs</i> , 2002, 62, 507-556.	4.9	69
167	Hepatitis C: Who Should You Treat and How?. <i>Blood Purification</i> , 2002, 20, 124-136.	0.9	2
169	Ribavirin with or without alpha interferon for chronic hepatitis C. <i>The Cochrane Library</i> , 2002, , CD002234.	1.5	7
170	Present treatment expectations and risks of chronic hepatitis C. <i>Clinical Microbiology and Infection</i> , 2002, 8, 74-79.	2.8	13
171	Emerging therapies of hepatitis B and C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S471-S481.	1.4	5
172	Treatment of chronic hepatitis C: Improved combination therapy. <i>Current Hepatitis Reports</i> , 2003, 2, 40-46.	0.3	2
173	Ribavirin in Cancer Immunotherapies: Controlling Nitric Oxide Augments Cytotoxic Lymphocyte Function. <i>Neoplasia</i> , 2003, 5, 3-8.	2.3	19

#	ARTICLE	IF	CITATIONS
174	Peginterferon-??-2a (40kD) Plus Ribavirin. <i>Drugs</i> , 2003, 63, 701-730.	4.9	49
175	Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2003, 3, 1169-1176.	1.7	28
176	Peginterferon-1±2a(40 kDa)/ribavirin combination for the treatment of chronic hepatitis C infection. <i>Expert Review of Anti-Infective Therapy</i> , 2003, 1, 423-431.	2.0	11
177	Evaluation of Nucleoside Phosphonates and Their Analogs and Prodrugs for Inhibition of Orthopoxvirus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2193-2198.	1.4	63
178	Clinical Trial Results of Peginterferons in Combination with Ribavirin. <i>Seminars in Liver Disease</i> , 2003, 23, 035-046.	1.8	25
179	Synergistic Inhibition of Intracellular Hepatitis C Virus Replication by Combination of Ribavirin and Interferon±. <i>Journal of Infectious Diseases</i> , 2004, 189, 1129-1139.	1.9	111
180	Impact of Alpha Interferon and Ribavirin on the Function of Maturing Dendritic Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3382-3389.	1.4	57
181	Sensitivity of Hepatitis C Virus RNA to the Antiviral Enzyme Ribonuclease L Is Determined by a Subset of Efficient Cleavage Sites. <i>Journal of Interferon and Cytokine Research</i> , 2004, 24, 664-676.	0.5	49
182	Antiviral action of ribavirin in chronic hepatitis C. <i>Gastroenterology</i> , 2004, 126, 703-714.	0.6	261
183	Ribavirin plus interferon versus interferon for chronic hepatitis C. , 2005, , CD005445.		17
184	Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. <i>Antiviral Research</i> , 2005, 67, 46-54.	1.9	26
185	Continued ribavirin monotherapy following interferon±ribavirin combination therapy is not effective for chronic hepatitis C. <i>Hepatology Research</i> , 2005, 32, 77-78.	1.8	0
186	Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. <i>Journal of Hepatology</i> , 2005, 43, 623-629.	1.8	111
187	Clinical experience with nonstandard doses ofinterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis. <i>Current Therapeutic Research</i> , 2005, 66, 433-450.	0.5	0
188	Tailoring immunosuppressants to hepatitis C virus±infected transplant patients. <i>Transplantation Reviews</i> , 2006, 20, 157-164.	1.2	0
189	Comparison of characteristics of treated and non-treated patients with Hepatitis C infection. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 71-76.	0.9	14
190	Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2006, 13, 190-198.	1.0	6
191	Cost-effectiveness of Chronic Hepatitis C Treatment with Thymosin Alpha-1. <i>Archives of Medical Research</i> , 2006, 37, 663-673.	1.5	13

#	ARTICLE	IF	CITATIONS
192	Therapy of hepatitis C: From empiricism to eradication. <i>Hepatology</i> , 2006, 43, S207-S220.	3.6	160
193	Viral Determinants of Resistance to Treatment in Patients with Hepatitis C. <i>Clinical Microbiology Reviews</i> , 2007, 20, 23-38.	5.7	142
194	Acute and Chronic Viral Hepatitis. , 0, , 369-446.		0
196	Phase 2 study of the combination of merimepodib with peginterferon- α 2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C. <i>Journal of Hepatology</i> , 2007, 47, 476-483.	1.8	26
197	Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2007, 14, 404-412.	1.0	21
198	Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus. <i>Journal of Dermatology</i> , 2007, 34, 577-582.	0.6	28
199	Rolling review“the pathogenesis, diagnosis and management of viral hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 1994, 8, 229-253.	1.9	10
200	Interferon-based therapy of hepatitis C. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 1222-1241.	6.6	73
201	Treatment strategy for hepatitis C after liver transplantation. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2008, 15, 111-123.	2.0	5
202	Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. <i>Liver International</i> , 2008, 28, 1332-1343.	1.9	77
203	Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase. <i>Journal of Viral Hepatitis</i> , 2008, 15, 571-577.	1.0	13
204	Ribavirin treatment for chronic hepatitis D: a pilot study. <i>Liver</i> , 1994, 14, 154-157.	0.1	56
206	Characterization of hepatocellular carcinoma developed after achieving sustained virological response to interferon therapy for hepatitis C. <i>Journal of Surgical Oncology</i> , 2009, 99, 32-37.	0.8	20
207	Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha α 2b plus ribavirin. <i>Journal of Viral Hepatitis</i> , 2009, 16, 586-594.	1.0	65
208	Ribavirin in chronic hepatitis C: past and future. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 249-253.	2.0	7
209	DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 805-815.	1.4	16
210	Brief Communication: Case Reports of Ribavirin Treatment for Chronic Hepatitis E. <i>Annals of Internal Medicine</i> , 2010, 153, 85.	2.0	155
211	Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. <i>Journal of Gastroenterology</i> , 2010, 45, 656-665.	2.3	23

#	ARTICLE	IF	CITATIONS
213	Viral Infections by Hepatotropic Viruses. , 2010 , 671-821.		1
214	ITPA gene variant protects against anemia induced by pegylated interferon- α and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatology Research, 2010, 40, 1063-1071.	1.8	63
215	Ribavirin plus interferon versus interferon for chronic hepatitis C. The Cochrane Library, 2010, , CD005445.	1.5	42
216	Ribavirin for chronic hepatitis C: And the mystery goes on. Digestive and Liver Disease, 2011, 43, 425-430.	0.4	22
217	1990-2010: Two Decades of Interferon-Based Therapy. Clinics in Liver Disease, 2011, 15, 473-482.	1.0	8
218	Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymorphisms in hepatitis C virus (HCV) infection. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1247-1256.	1.4	18
219	Ribavirin Enhances IFN- α Signalling and MxA Expression: A Novel Immune Modulation Mechanism during Treatment of HCV. PLoS ONE, 2011, 6, e27866.	1.1	44
220	Oligomeric Nucleic Acids as Antivirals. Molecules, 2011, 16, 1271-1296.	1.7	32
221	Pharmacological and Biological Antiviral Therapeutics for Cardiac Coxsackievirus Infections. Molecules, 2011, 16, 8475-8503.	1.7	33
222	Fighting against viral hepatitis: Lessons from Taiwan. Hepatology, 2011, 54, 381-392.	3.6	61
223	Boceprevir and personalized medicine in hepatitis C virus infection. Pharmacogenomics and Personalized Medicine, 2012, Volume 5, 125-137.	0.4	4
224	The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C. Antiviral Chemistry and Chemotherapy, 2012, 23, 1-12.	0.3	109
225	Hepatitis C Therapy: Lessons of the Last Two Decades. Current Hepatitis Reports, 2012, 11, 119-127.	0.3	1
227	Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment. Annals of Hepatology, 2012, 11, 827-837.	0.6	6
228	Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C. Hepatology International, 2013, 7, 153-161.	1.9	4
229	Guidelines for the Management of Hepatitis C Virus Infection. Hepatology Research, 2013, 43, 1-34.	1.8	56
230	25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nature Reviews Immunology, 2013, 13, 535-542.	10.6	134
231	Ribavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring. Advances in Hepatology, 2014, 2014, 1-13.	1.3	10

#	ARTICLE	IF	CITATIONS
233	Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: Direct sequencing and pyrosequencing of the HCV regions. <i>Journal of Medical Virology</i> , 2014, 86, 1886-1897.	2.5	5
234	A brief history of hepatitis milestones. <i>Liver International</i> , 2014, 34, 29-37.	1.9	63
235	Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 148-162.	1.9	14
236	New Hepatitis C Virus (HCV) Drugs and the Hope for a Cure: Concepts in Anti-HCV Drug Development. <i>Seminars in Liver Disease</i> , 2014, 34, 022-029.	1.8	89
237	What is the future of ribavirin therapy for hepatitis C?. <i>Antiviral Research</i> , 2014, 104, 34-39.	1.9	41
238	Chutes and ladders in hepatitis C nucleoside drug development. <i>Antiviral Research</i> , 2014, 102, 119-147.	1.9	69
239	Treatment of chronic hepatitis C: What is new?. <i>Apollo Medicine</i> , 2014, 11, 93-102.	0.0	1
240	Aminoadamantanes for chronic hepatitis C. <i>The Cochrane Library</i> , 2014, , CD010125.	1.5	2
241	Aminoadamantanes versus other antiviral drugs for chronic hepatitis C. , 2014, , CD011132.		4
242	History and progress of antiviral drugs: From acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C. <i>Medicina Universitaria</i> , 2015, 17, 165-174.	0.1	32
243	Management of HCV in Cirrhosis—a Rapidly Evolving Landscape. <i>Current Gastroenterology Reports</i> , 2015, 17, 443.	1.1	3
244	From non-A, non-B hepatitis to hepatitis C virus cure. <i>Journal of Hepatology</i> , 2015, 62, S87-S99.	1.8	284
245	Direct-Acting Antiviral Agents. <i>Clinics in Liver Disease</i> , 2015, 19, 629-639.	1.0	1
246	Hepatitis C Virus. , 2016, , 1313-1345.		61
247	Telaprevir: From Drug Discovery to the Manufacture of Drug Substance. <i>ACS Symposium Series</i> , 2016, , 281-323.	0.5	1
248	Hepatitis C: a successful story of cure. <i>Science Bulletin</i> , 2016, 61, 1884-1887.	4.3	1
249	Bicyclic octahydrocyclohepta[b]pyrrol-4(1 H)one derivatives as novel selective anti-hepatitis C virus agents. <i>European Journal of Medicinal Chemistry</i> , 2016, 122, 319-325.	2.6	6
250	Approaches and Considerations for the Successful Treatment of HCV Infection. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
251	Ribavirin: pharmacology, multiple modes of action and possible future perspectives. <i>Future Virology</i> , 2019, 14, 153-160.	0.9	53
252	The Evolution of Clinical Trials for Hepatitis C. <i>Topics in Medicinal Chemistry</i> , 2019, , 187-235.	0.4	0
253	Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent. <i>Virology</i> , 2020, 540, 132-140.	1.1	10
254	Evolution and Revolution of Hepatitis C Management: From Non-A, Non-B Hepatitis Toward Global Elimination. <i>Digestive Diseases</i> , 2020, 38, 137-142.	0.8	19
255	Squaramides as Bioisosteres in Contemporary Drug Design. <i>Chemical Reviews</i> , 2020, 120, 11616-11650.	23.0	31
256	Role of Ribavirin in the Era of Direct-Acting Antiviral Therapies of Chronic Hepatitis C. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 817-822.	2.0	3
257	Global hepatitis C elimination: history, evolution, revolutionary changes and barriers to overcome. <i>Romanian Journal of Morphology and Embryology</i> , 2021, 61, 643-653.	0.4	8
258	Infection in Relation to Thoracic Transplantation. , 1996, , 281-311.		1
259	Non-A, Non-B Hepatitis in Dialysis Patients: Diagnosis, Prevention and Treatment. , 1991, , 253-270.		4
260	Treatment of Chronic Hepatitis C Virus Infection: A Clinical and Virological Perspective. <i>Advances in Experimental Medicine and Biology</i> , 1996, 394, 207-224.	0.8	5
261	Ribavirin or Alpha Interferon Treatment of Chronic Hepatitis C: Assessment of Antiviral Efficacy. , 1994, , 642-646.		5
262	Hepatitis C Virus Genotypes: An Investigation of Type-specific Differences in Geographic Origin and Disease. , 1994, , 301-305.		2
263	Ribavirin therapy for hepatitis C infection following liver transplantation. <i>Transplant International</i> , 1995, 8, 61-64.	0.8	28
264	THERAPY FOR CHRONIC HEPATITIS C. <i>Gastroenterology Clinics of North America</i> , 1994, 23, 603-613.	1.0	26
265	Pre- and post-transplant treatment of hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, E187-E193.	1.4	2
266	Firstline treatment for hepatitis C: combination interferon/ribavirin versus interferon monotherapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, E130-E133.	1.4	6
267	Editorial: Interferon Therapy for Chronic HCV Hepatitis: Trick or Treat?. <i>Journal of Clinical Gastroenterology</i> , 1997, 25, 310-313.	1.1	1
268	The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses.. <i>Journal of General Virology</i> , 1998, 79, 2381-2391.	1.3	251

#	ARTICLE	IF	CITATIONS
269	Section Review Anti-infectives: Current perspectives on the treatment and prevention of hepatitis C infection. Expert Opinion on Investigational Drugs, 1996, 5, 1657-1671.	1.9	5
270	Transmission of the hepatitis-C virus by tissue transplantation.. Journal of Bone and Joint Surgery - Series A, 1995, 77, 214-224.	1.4	269
271	Treatment Guidelines of Hepatitis C. Acta Hepatologica Japonica, 2012, 53, 355-395.	0.0	2
272	Combination of low-dose ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapy. World Journal of Gastroenterology, 2001, 7, 222.	1.4	11
273	Is the 25-year hepatitis C marathon coming to an end to declare victory?. World Journal of Hepatology, 2017, 9, 921.	0.8	6
274	Chronic Hepatitis C Treatment: A Review. Annals of Saudi Medicine, 2000, 20, 402-408.	0.5	5
275	Interferon treatment for chronic viral hepatitis in Australia: is it worth it?. Medical Journal of Australia, 1992, 156, 873-876.	0.8	10
276	Incidence and treatment of recurrent hepatitis C after liver transplantation. Journal of Transplant Coordination, 1996, 6, 24-27.	0.2	5
278	Symptomatic therapies for prevention of hepatocellular carcinoma developing in chronic hepatitis C. , 2003, , 515-530.		0
279	Study on Decreased Hemoglobin Levels in Combination Therapy with Interferon .ALPHA.-2b and Ribavirin for Chronic Hepatitis C.. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq1 1 00784314 rgBT /Overl		0
280	Current and Future Therapy of Chronic Hepatitis C. , 2009, , 71-96.		0
282	Interferon Alfa. , 2010, , 2959-2975.		0
283	New Therapeutic Strategies for Chronic Hepatitis. , 1992, , 263-288.		0
285	Hepatitis C and hepatitis E: prevention, prophylaxis and treatment. , 1993, , 194-201.		0
286	Treatment of Viral Infections in the Human Immunodeficiency Virus-Infected Patient. , 1994, , 469-490.		0
287	Interferon Therapy of Viral Hepatitis. , 1996, , 77-89.		5
288	Immunological Features and the Effect of Interferon Treatment in Chronic Hepatitis C. , 1997, , 287-303.		0
290	The clinical virology of hepatitis C virus. International Journal of Experimental Pathology, 1994, 75, 61-9.	0.6	1

#	ARTICLE	IF	CITATIONS
291	Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection: Anti-HCV therapy and autonomic function. Hepatitis Monthly, 2011, 11, 114-8.	0.1	5
292	Breakthroughs in hepatitis C research: from discovery to cure. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 533-550.	8.2	62
293	Chronic Hepatitis C. Medical Clinics of North America, 2023, 107, 423-433.	1.1	3